Benjamin H Lok1, Ginger Jiang2, Stanley Gutiontov3, Ryan M Lanning1, Sudeepta Sridhara1, Eric J Sherman4, Chiaojung Jillian Tsai1, Sean M McBride1, Nadeem Riaz1, Nancy Y Lee5. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. 2. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA. 3. Feinberg School of Medicine - Northwestern University, 303 E Chicago Avenue, Chicago, IL 60611, USA. 4. Department of Medical Oncology, Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center, USA. 5. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: LeeN2@mskcc.org.
Abstract
OBJECTIVES: To report on our institutional experience of palliative radiotherapy (RT) of cancers in the head and neck by the RTOG 8502 'QUAD SHOT' regimen. METHODS: Seventy-five patients completed at least 1 cycle of palliative RT to the head and neck for primary or metastatic disease based on the RTOG 8502 regimen (3.7 Gy twice daily over 2 consecutive days at 4 week intervals per cycle) between 2/2005 and 7/2014. RESULTS: Median patient age was 76 years (range 23-97). The most common histologies were squamous cell carcinoma (55%), non-anaplastic thyroid carcinoma (10%) and salivary gland carcinoma (9%). Thirty patients (40%) received prior RT at the palliative site. Twenty-eight patients (37%) completed at least three RTOG 8502 cycles. Sixty-five percent of all patients had a palliative response. Median overall survival was 5.67 months (range, 0.20-34.5). Grade 3 toxicity in 4 patients (5%) consisted of acute dermatitis and functional mucositis. Palliative response was significantly correlated with increasing number of RTOG 8502 cycles (p = 0.012), but not KPS, prior RT, palliative chemotherapy, prior surgery, histology or stage. On survival analysis, palliative response (p < 0.001), KPS ⩾ 70 (p = 0.001), and greater number of RTOG 8502 cycles (p = 0.022) remained independent predictors of improved survival. CONCLUSIONS: For patients with incurable malignant disease in the head and neck, the palliative RTOG 8502 'QUAD SHOT' regimen provides excellent rates of palliative response with minimal associated toxicity. Patients who are able to complete greater number of RT cycles have higher rates of palliative response and overall survival.
OBJECTIVES: To report on our institutional experience of palliative radiotherapy (RT) of cancers in the head and neck by the RTOG 8502 'QUAD SHOT' regimen. METHODS: Seventy-five patients completed at least 1 cycle of palliative RT to the head and neck for primary or metastatic disease based on the RTOG 8502 regimen (3.7 Gy twice daily over 2 consecutive days at 4 week intervals per cycle) between 2/2005 and 7/2014. RESULTS: Median patient age was 76 years (range 23-97). The most common histologies were squamous cell carcinoma (55%), non-anaplastic thyroid carcinoma (10%) and salivary gland carcinoma (9%). Thirty patients (40%) received prior RT at the palliative site. Twenty-eight patients (37%) completed at least three RTOG 8502 cycles. Sixty-five percent of all patients had a palliative response. Median overall survival was 5.67 months (range, 0.20-34.5). Grade 3 toxicity in 4 patients (5%) consisted of acute dermatitis and functional mucositis. Palliative response was significantly correlated with increasing number of RTOG 8502 cycles (p = 0.012), but not KPS, prior RT, palliative chemotherapy, prior surgery, histology or stage. On survival analysis, palliative response (p < 0.001), KPS ⩾ 70 (p = 0.001), and greater number of RTOG 8502 cycles (p = 0.022) remained independent predictors of improved survival. CONCLUSIONS: For patients with incurable malignant disease in the head and neck, the palliative RTOG 8502 'QUAD SHOT' regimen provides excellent rates of palliative response with minimal associated toxicity. Patients who are able to complete greater number of RT cycles have higher rates of palliative response and overall survival.
Authors: Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper Journal: N Engl J Med Date: 2003-11-27 Impact factor: 91.245
Authors: Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: Jacques Bernier; Christian Domenge; Mahmut Ozsahin; Katarzyna Matuszewska; Jean-Louis Lefèbvre; Richard H Greiner; Jordi Giralt; Philippe Maingon; Frédéric Rolland; Michel Bolla; Francesco Cognetti; Jean Bourhis; Anne Kirkpatrick; Martine van Glabbeke Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: B Brockstein; D J Haraf; A W Rademaker; M S Kies; K M Stenson; F Rosen; B B Mittal; H Pelzer; B B Fung; M-E Witt; B Wenig; L Portugal; R W Weichselbaum; E E Vokes Journal: Ann Oncol Date: 2004-08 Impact factor: 32.976
Authors: W J Spanos; M Clery; C A Perez; P W Grigsby; R L Doggett; C A Poulter; A D Steinfeld Journal: Int J Radiat Oncol Biol Phys Date: 1994-07-30 Impact factor: 7.038
Authors: Anneke Fryen; Iris Brandes; Jörn Wichmann; Hans Christiansen; Frank Tavassol; Martin Durisin; Roland Merten Journal: In Vivo Date: 2022 May-Jun Impact factor: 2.406
Authors: Jennifer Ma; Jeremy Setton; Luc Morris; Pedro Blecua Carrillo Albornoz; Christopher Barker; Benjamin H Lok; Eric Sherman; Nora Katabi; Kathryn Beal; Ian Ganly; Simon N Powell; Nancy Lee; Timothy A Chan; Nadeem Riaz Journal: Oncotarget Date: 2017-02-07
Authors: Amy J Xu; Leo Luo; Jonathan E Leeman; Paul B Romesser; Daniel Spielsinger; Christopher Sabol; Todd Waldenberg; Thomas Brinkman; Nadeem Riaz; Sean McBride; Julie Kang; Nancy Lee; Chiaojung Jillian Tsai Journal: Clin Transl Radiat Oncol Date: 2020-04-24
Authors: Jennifer Ma; Benjamin H Lok; Jingfeng Zong; Stanley I Gutiontov; Xin Cai; Andrew C Bell; Marina Shcherba; Han Xiao; Eric J Sherman; Chiaojung Jillian Tsai; Nadeem Riaz; Sean M McBride; Oren Cahlon; Nancy Y Lee Journal: Int J Part Ther Date: 2018
Authors: Aline Lauda Freitas Chaves; Ana Ferreira Castro; Gustavo Nader Marta; Gilberto Castro Junior; Robert L Ferris; Raúl Eduardo Giglio; Wojciech Golusinski; Philippe Gorphe; Sefik Hosal; C René Leemans; Nicolas Magné; Hisham Mehanna; Ricard Mesía; Eduardo Netto; Amanda Psyrri; Assuntina G Sacco; Jatin Shah; Christian Simon; Jan B Vermorken; Luiz Paulo Kowalski Journal: Oral Oncol Date: 2020-04-24 Impact factor: 5.337
Authors: Alexander Fabian; Justus Domschikowski; Markus Hoffmann; Oliver Weiner; Claudia Schmalz; Jürgen Dunst; David Krug Journal: Front Oncol Date: 2021-06-04 Impact factor: 6.244